UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $184.00 and last traded at $184.00, with a volume of 230 shares traded. The stock had previously closed at $184.00.
UCB Stock Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average price of $179.85 and a two-hundred day moving average price of $154.93.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Using the MarketBeat Stock Split Calculator
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is Put Option Volume?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What are earnings reports?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
